Eligible subjects must have a diagnosis of BED according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1:1 ratio to receive solriamfetol (150 or 300 mg) or placebo, once daily for 12 weeks.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary diagnosis of BED according to DSM-5 criteria.
Provides written informed consent to participate in the study before the conduct of any study procedures.
Male or female, aged 18 to 55 inclusive.
You may not be if
Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
Unable to comply with study procedures.
Medically inappropriate for study participation in the opinion of the investigator.
